文献速递帕金森病与运动障碍

增加卡比多巴剂量联合左旋多巴和恩他卡朋改善帕金森病「关」期

Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.
PubMed 文献 · Neurology · 2019-03-01

结果显示,增加卡比多巴剂量可更显著减少每日「关」时间并增加无麻烦性异动症的「开」时间,安全性和耐受性无差异。

要点

  • 增加卡比多巴剂量可改善波动性帕金森病患者的每日「关」时间。
  • 高活性COMT基因型(Val/Met或Val/Val)患者获益更明显。
  • 增加卡比多巴剂量未增加麻烦性异动症或安全性问题。

核心结论

  • 在波动性帕金森病患者中,增加卡比多巴剂量联合左旋多巴和恩他卡朋可改善每日「关」时间。
  • 根据COMT活性对帕金森病患者进行基因分型可能改善个体化治疗策略。

研究设计与样本

  • 随机、双盲、双模拟、活性对照、交叉、多中心II期概念验证研究。
  • 治疗4周,比较固定卡比多巴剂量65或105 mg联合左旋多巴和恩他卡朋与标准4:1左旋多巴/卡比多巴联合恩他卡朋。

主要发现

  • 携带校正后平均「关」时间较基线变化:ODM-101/65为-1.53小时(vs LCE p=0.02),ODM-101/105为-1.57小时(vs LCE p=0.01),LCE为-0.91小时。
  • 每日无麻烦性异动症「开」时间变化:ODM-101/65为1.54小时(vs LCE p=0.005),ODM-101/105为1.38小时(vs LCE p=0.0214),LCE为0.69小时。
  • 麻烦性异动症「开」时间变化均<0.1小时,组间无显著差异。
  • 高活性COMT基因型(Val/Met或Val/Val)患者中,ODM-101/65和ODM-101/105较LCE更显著减少「关」时间(p=0.015和p=0.006)。
  • 安全性和耐受性组间无差异;最常见治疗相关不良事件为恶心、头晕、药效下降和异动症,多为轻中度。

关键数值与推荐

  • 研究提供II级证据表明增加卡比多巴剂量联合左旋多巴和恩他卡朋可改善运动波动。
  • 临床试验注册号:NCT01766258。

临床怎么用

  • 在波动性帕金森病患者中可考虑增加卡比多巴剂量以改善每日「关」时间。
  • 可根据COMT活性对帕金森病患者进行基因分型以优化个体化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether increased fixed carbidopa doses of 65 or 105 mg (ODM-101/65 and ODM-101/105) in combination with 75, 100, 125, or 150 mg of levodopa and 200 mg of entacapone might improve "off" time in fluctuating Parkinson disease (PD) compared to the standard combination of 4:1 levodopa/carbidopa with the usual 200 mg of entacapone (LCE) during a 4-week treatment period. METHODS: This was a randomized, double-blind, double-dummy, active-controlled, crossover, multicenter, phase II, proof-of-concept study in patients with fluctuating PD. RESULTS: One hundred seventeen patients were randomized into the study (mean age 67.0 years; daily "off" time 5.3 hours; mean daily levodopa dose 610 mg). Carryover-adjusted mean changes from baseline "off" times were during ODM-101/65, -1.53 hours (p = 0.02 vs LCE), during ODM-101/105, -1.57 hours (p = 0.01 vs LCE), and during LCE -0.91 hours. Changes in daily "on" time without dyskinesia were 1.54 hours (p = 0.005 vs LCE), 1.38 hours (p = 0.0214 vs LCE), and 0.69 hours, respectively. Changes in "on" time with troublesome dyskinesia were <0.1 hours and not significantly different between treatments. In patients with high-activity COMT genotypes Val/Met or Val/Val, "off" time was reduced more with ODM-101/65 and ODM-101/105 than with LCE (p = 0.015 and p = 0.006). No difference between the treatments was seen in safety and tolerability. The most common treatment-related adverse effects were nausea, dizziness, drug-effect decrease, and dyskinesia, which were in most cases mild or moderate in severity. Treatment-related serious adverse events were diarrhea (ODM-101/105 and LCE), and myocardial ischemia and blood creatine kinase increase (LCE). CONCLUSION: Increasing the dose of carbidopa in combination with levodopa and entacapone should be considered in the treatment of fluctuating PD to improve daily "off" times. Genotyping patients with PD according to COMT activity may improve individual treatment strategies. CLINICALTRIALSGOV IDENTIFIER: NCT01766258. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that an increased dose of carbidopa improves motor fluctuations when administered with levodopa and entacapone.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Trenkwalder C, Kuoppamäki M, Vahteristo M, et al. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial. Neurology. 2019. PMID: 30824559. doi:10.1212/WNL.0000000000007173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。